NCT01634243CompletedPhase 2
A Open-label Dose-ranging Study for SPM 962 in Parkinson's Disease Patients
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 64
- Primary Endpoint
- Maintenance Dose of the SPM962
Study Overview
Brief Summary
The primary objective of this trial is to establish the maximum maintenance dose of SPM 962 in patients with Parkinson's disease in a multi-center, uncontrolled, open-label study by conducting safety evaluation of each patient following once-daily transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg. (The administration period will consist of a standard 8-week dose-titration period, 4-week dose-maintenance period, and a dose de-escalation period) Exploratory evaluation of each patient's maintenance dose will also be conducted with attention to patient safety. The relationship of pharmacokinetics, safety, and efficacy will also be examined.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 30 Years to 79 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •For subject with early and advanced Parkinson's disease
- •Subject diagnosed as having Parkinson's disease in accordance with "Diagnostic Criteria established by the Research Committee of MHLW-specified Intractable Neurodegenerative Diseases (1995)".
- •Subject is 30 and more and less than 80 years of age at the time of informed consent.
- •Gender and inpatient-outpatient status are not specified.
- •For subject with early Parkinson's disease
- •Hoehn & Yahr stage 3 or less.
- •Subject who has not taken L-dopa within 28 days prior to initial administration of SPM
- •For subject with dvanced Parkinson's disease
- •Hoehn & Yahr stage 2-
- •Subject is on a stable dose of L-dopa with no change in daily dose or dosing regimen for at least 7 days prior to the initial treatment of SPM
- •Subject has any of the following problematic symptoms; 1) Wearing off phenomenon 2) On and off phenomenon 3) Not well controlled with L-dopa due to adverse effect 4) Weakening of L-dopa efficacy.
Exclusion Criteria
- •Subject is on other dopamine agonist treatment within 7 days prior to the initial treatment. Subject is on cabergoline treatment within 14 days prior to the initial treatment.
- •Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior.
- •Subject has orthostatic hypotension.
- •Subject has a history of epilepsy, convulsion and other.
- •Subject has a complication of serious cardiac disorder or has the history.
- •Subject has arrhythmia and treated with class 1a antiarrhythmic drugs (e.g. quinidine, procainamide etc.) or class 3 antiarrhythmic drugs (e.g. amiodarone, sotalol etc.).
- •At screening and baseline, subject develops serious ECG abnormality. Subjects has QTc-interval >450 msec at screening. Subject has QTc-interval >450 msec in males and >470 msec in females at baseline.
- •Subject has congenital long QT syndrome.
- •Subject has hypokalaemia.
- •Subject has a total bilirubin >= 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or >= 100 IU/L).
- •Subject has BUN >= 25 mg/dL or serum creatinine >= 2.0 mg/dl.
- •Subject has a history of allergic reaction to topical agents such as transdermal patch.
- •Subject is pregnant or nursing or woman who plans pregnancy during the trial.
- •Subject is receiving therapy with prohibited drug specified in the study protocol.
- •Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
- •Subject has dementia.
- •Subject is unable to give consent.
- •Subject is participating in another trial of an investigational drug or done so within 6 months prior to the initial treatment.
- •Investigator judges that subject is inappropriate as a study subject with other reasons.
Arms & Interventions
SPM 962
Experimental
SPM 962 transdermal patch
Intervention: SPM 962 (Drug)
Outcomes
Primary Outcomes
Maintenance Dose of the SPM962
Time Frame: Up to 12 weeks after dosing
The maintenance dose of the SPM 962 was examined based on the safety and efficacy.
Secondary Outcomes
- Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters(Up to 12 weeks after dosing)
- Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy(baseline, 12 weeks after dosing)
- UPDRS Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy(baseline, 12 weeks after dosing)
- UPDRS Part 2 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy(Baseline, 12 weeks after dosing)
- UPDRS Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy(Baseline, 12 weeks after dosing)
- UPDRS Part 2 Sum Score (on State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.(Baseline, 12 weeks after dosing)
- UPDRS Part 2 Sum Score (Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.(Baseline, 12 weeks after dosing)
- UPDRS Part 2 Sum Score (Average Score of on State and Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy(Baseline, 12 weeks after dosing)
- Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy(Baseline, 12 weeks after dosing)
- Off Time for Advanced Parkinson's Disease With Concomitant L-dopa Therapy(Baseline, 12 weeks after dosing)
Investigators
Similar Trials
Completed
Phase 2
A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease PatientsParkinson's DiseaseNCT01628848Otsuka Pharmaceutical Co., Ltd.174
Completed
Phase 2
A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs SyndromeIdiopathic Restless Legs SyndromeNCT01562743Otsuka Pharmaceutical Co., Ltd.185
Completed
Phase 2
A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease PatientsParkinson's DiseaseNCT01631812Otsuka Pharmaceutical Co., Ltd.130
Completed
Phase 2
Rotigotine Restless Legs Syndrome Dose Finding TrialIdiopathic Restless Leg SyndromeNCT00243217UCB Pharma341
Terminated
Phase 1
A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic AdenocarcinomaNCT05484011HiberCell, Inc.5